chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe chest pain in the the middle of my chest lasting more than five minutes. The first episode was just a minute long, second was more than 5 minutes; Day following chest is tight; This is a spontaneous report from a contactable consumer or other non hcp (patient reported for herself). A 49-year-old adult female patient (non-pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: EW0170), dose 2 via an unspecified route of administration, administered in Arm Left on 24Apr2021 at 13:30 (at the age of 49-year-old) as DOSE 2, SINGLE for covid-19 immunisation. The patient was not pregnant at the time of vaccination. Medical history included asthma from an unknown date and unknown if ongoing and covid-19 from an unknown date and unknown if ongoing. The patient had no known allergies. Concomitant medication(s) included Salbutamol (ALBUTEROL HFA); Fluticasone propionate (FLONASE [FLUTICASONE PROPIONATE]) and Escitalopram oxalate (LEXAPRO), all taken for an unspecified indication, start and stop date were not reported. The patient previously received her first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: ER8T34), via an unspecified route of administration, administered in Arm Left on 03Apr2021 at 01:15 PM (at the age of 49-year-old) as single dose for covid-19 immunisation and experienced swollen lymph nodes. No other vaccine in four weeks. The patient had not been covid tested post vaccination. On 26Apr2021 at 07:00 AM, the patient experienced severe chest pain in the middle of my chest lasting more than five minutes. The first episode was just a minute long, second was more than 5 minutes. The clinical details of the events as follows: Severe chest pain in the middle of my chest lasting more than five minutes. The first episode was just a minute long, second was more than 5 minutes. She was checked for heart and blood clot, none found. Day following chest was tight like when she had COVID last year. She stated it may not be related, but wanted to report in case, as there was not another reason, she can tie to this. She had reactions 48 hours after first dose with need for inhaler and swollen lymph nodes. AE resulted in Emergency room/department or urgent care. AE treatment included Emergency room, work up for heart concern. The patient outcome of the events was Resolved with Sequel (lasting effects).  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Patient received the first dose of the Pfizer vaccine on 29JAN21 and received the second dose on 29MAY21. No adverse reaction to either dose.
Hospitalized on 30Jan2021 for COVID pneumonia; Cannot support standing and walking and vocal cords not fully closed yet; Cannot support standing and walking and vocal cords not fully closed yet; Cannot support standing and walking and vocal cords not fully closed yet; Weakness; confusion; This is a spontaneous report from a contactable consumer (patient himself). A 77-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EL8982), via an unspecified route of administration in right arm on 18Jan2021 at 14:00 (at the age of 77-year-old) as a single dose for COVID-19 immunization. The patient's medical history included AFib, high blood pressure. Concomitant medications included apixaban (ELIQUIS), hydrazaline hydrochloride (APRESOLINE), losartan potassium (COZAAR) and metoprolol; All received within 2 weeks of vaccination. The patient previously took lisinopril and experienced known allergies: Lisinopril. Allergies to medications, food, or other products: Lisinopril. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient diagnosed with COVID-19 was unknown. Since the vaccination, the patient been tested for COVID-19 was unknown. The patient did not receive other vaccine in four weeks. Hospitalized on 30Jan2021 for COVID pneumonia which occurred on 24Jan2021 at 08:00 AM and put on ventilator on 05Feb2021. 18 days on ventilator, ICU and released to hospital. On 17Mar2021 admitted to hospital for speech, occupational, and physical therapy. Cannot support standing and walking and vocal cords not fully closed yet on 24Jan2021 at 08:00 AM. Weakness and some confusion on 24Jan2021 at 08:00 AM. The adverse events resulted in emergency room/department or urgent care. The patient was hospitalized for 55 days. The events were considered as serious (hospitalization and disability or permanent damage) by the consumer. The patient was treated with medications and ventilator for the adverse events. The outcome of the events was not recovered.   Information on the lot/batch number has been requested.
developed a weird taste in my mouth. Taste like metal and salt.; developed a weird taste in my mouth. Taste like metal and salt.; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old patient of unknown gender received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Gr8734) via an unspecified route of administration in the left arm on 07Apr2021 at 10:30(at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included ibuprofen (ADVIL) and paracetamol (TYLENOL); both from unknown indication and start date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 07Apr2021 at 10:45, the patient developed a weird taste in mouth which tasted like metal and salt. The patient did not receive any treatment for the events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event developed a weird taste in mouth which tasted like metal and salt were not resolved.   No follow-up attempts are needed. No further information is expected.  Amendment: This follow-up report is being submitted to amend previously reported information: First name of reporter slide#2 removed and moved to Institution field. Best doctor phone added.
EXPIRED VACCINE USED / PRODUCTS HAD REACHED THEIR LISTED EXPIRATION DATES; This spontaneous report received from a health care professional concerned multiple patients. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 213D21A expiry: 08-SEP-2022) dose was not reported, administered on 06-OCT-2022 for covid-19 prophylaxis. The drug was associated with Drug taken beyond expiry date. No concomitant medications were reported.  On 06-OCT-2022, the patient experienced expired vaccine used / products had reached their listed expiration dates. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired vaccine used / products had reached their listed expiration dates was not reported. This report was non-serious. This case, from the same reporter is linked to 20230149982, 20230150157, 20230150423, 20230150588, 20230150600, 20230150716, 20230150777 and 20230150255.
woke up with racing hard heart beat, nauseous vomiting at mid night through up til 3am felt some better. still slightly sick and tired.
I had my vaccination on 09/15/2022. On 02/22/2023 I had blood in my urine. This lasted for approximately 10 hours. I waited until 02/23/2023 to seek medical attention at an urgent care. I was prescribed antibiotics. I presently do not feel great on 03/28/2023. I feel a dull pain in my back. I am still waiting for the test results from 03/24/2023. I am scheduled for a cystoscopy on 03/29/2023.
This spontaneous report as received from an Emergency medical technician (E.M.T.) refers to an unspecified number of patients of unknown ages. On an unknown date, the unspecified number of patients were vaccinated with improperly stored doses of GARDASIL (doses, routes, lot numbers and indications were not reported). No concomitant medications were reported. On an unknown date, reported as "starting July 12", GARDASIL was exposed to 31F for a maximum of 15 hours; On an unknown date, reported as 'in August", GARDASIL was exposed to 54F for 15 hours. The reporter stated that there have been additional temperature excursions since then, and patients had received doses of the improperly stored GARDASIL. Additional information has been requested.
Moderna vaccine administered to 17 year old. First dose was administered on 3/24/2021 by Hospital.
Facial changes mimicking cerebral palsy. Eyes either swollen or other for smaller. Left side of face feels?. Lazy.
intense flu-like symptoms started suddenly...chills, weakness, joint pain in all my joints...fatigue. Symptoms started about 9:30 am Saturday 09jan2021, patient (I) took a Tylenol and went to bed curled into a ball and shivering under a pile of blankets.....spent most of the day in bed.  Felt very badly.  Got up about 4:30 pm ad felt a little bit better (no more chills..just joint pain and weakness)....made some dinner..and about 7pm the chills started again (joint pain still present)...I took a Tylenol...and I rushed back to bed...again curled into a small freezing ball...slept fitfully...finally got up about 8:30 am on Sunday morning (10jan)....still feeling weakness and slight joint pain.  All symptoms abated by approximately 11:30 am on Sunday 10Jan2021
Fever of 103 F, received Tylenol, then developed tonic-clonic seizure activity for about 20 minutes (received  10mg intranasal midazolam and 0.5mg buccal clonazepam while awaiting EMS)
This case was reported by a pharmacist via sales rep and described the occurrence of injection site wheal in a patient who received FLULAVAL QUADRIVALENT. On an unknown date, the patient received FLULAVAL QUADRIVALENT. On an unknown date, unknown after receiving FLULAVAL QUADRIVALENT, the patient experienced injection site wheal, injection site pain and injection site swelling. On an unknown date, the outcome of the injection site wheal, injection site pain and injection site swelling were unknown. It was unknown if the reporter considered the injection site wheal, injection site pain and injection site swelling to be related to FLULAVAL QUADRIVALENT. Additional details were reported as follows: The age at vaccination was not reported. The age at vaccination was not reported. The sales representative believed that the flu vaccine received by the patient was the FLULAVAL QIV Pre Filled Syringe. The patient complained of a 2 inch welt, soreness, and swelling at the injection site. The sales representative had no patient identifies or lot and expiration date of the vaccine. The health care professional could be contacted directly for further information. This was one of the cases, reported by the same reporter.
Pt received second dose of series 14 days early.   Pt has no symptoms at this time. Pt informed to monitor symptoms and to return to clinic if any concerns.   VAERS report line called.
Patient reported numbness and tingling on left side of her throat ad tongue about 20 minutes after her shot. Vital signs stable. Patient then reported feeling dizzy, lightheaded, and weak. No hives, itching, or swelling at site. Patient requested to go to the emergency department and she was transferred there.
5 weeks after second Pfizer shot I began experiencing un-explained dizziness and bilateral arm numbness. It has lasted more than 2 weeks now.
Hospitalized 10/27/2021; COVID-19 positive 10/27/2021; fully vaccinated  BRIEF OVERVIEW:  Admission Date: 10/27/2021 Discharge Date: 11/5/21 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Hypoxia [R09.02] Pneumonia due to COVID-19 virus [U07.1, J12.82] COVID-19 [U07.1] HOSPITAL COURSE Patient s a 81 y.o. female with past medical history of coronary artery disease, EF 55%, COPD who presented with hypoxia and altered mental status due to COVID encephelopathy in the setting of COVID infection. Husband reported 2 weeks of cough, diarrhea and confusion. Husband also reported mild dementia before this however pt was more altered than baseline dementia. CXR showed bilateral opacities. Treated with decadron. Was outside the window for remdesivir. Pt was diuresed during the admission.  Pt had mitts, restraints, seroquel was given due to encephelopathy and removing oxygen which cause her to desat to the 70's on multiple occasions.   Over multiple days patient began to become less encephalopathic and required less oxygen.  On 11/04 patient was fully awake and oriented on exam is, was conversing with her husband in the afternoon, was able to eat by herself and create linear conversations.  We observed her for 1 more day and to complete her steroid treatment.  Patient was discharged on 11/05 in stable condition for home with assist.
Information has been received from a physician's receptionist concerning her husband who was vaccinated with ZOSTAVAX. The receptionist at the physician's office reported her husband experienced injection site reaction after receiving the ZOSTAVAX. This report is one of two reports received from the same source. Additional information is not expected.
1st dose: extremely sore & tender arm 2nd dose: few hour after shot, had a very sore arm. Next day woke up with fever, chills & flu like symptoms, along with extreme pain throughout entire body. 3rd day, extreme vertigo, low grade fever (99-100.2) still having body aches but not as bad as 1st & second day.
Incident occurred at 6:45 pm after administering the Pfizer vaccine. Thee patient complained of dizziness and nausea. Checked blood pressure which was 110/80. Gave patient water and he vomited right after. Patient said he felt better after vomiting. He was able to walk without assistance and said he was fine to go home. Time course was approximately 15 minutes.
Pt reported feeling pain in injection site & tingling sensation in fingers of injection site hand. Pharmacist on duty advised pt to see dr. Pt saw ER physician who prescribed 3 medications for rxn.
23OCT92 pt devel rhinitis & then nasal congestion; 24OCT92 little red spots appeared on cheeks on which faded in 24 hrs; 27OCT92 pt devel fever @ 7AM which porgressed to 105 by 10AM; pt is listless w/high fevers; mom must given APAP;
Fever 100+ Chills Aching muscles/joints Sore arm at injection site Headache Backache
Patient developed drooping of the right side of his face with drooping of the corner of the mouth and scratchy sensation with droopiness of the right eye. Symptoms started yesterday and presented to the office today. Has a history of Bell's Palsy in 2020. 2nd booster vaccine was given earlier this week at a health department.
Soreness in muscles; Soreness at injection site; This is a spontaneous report received from a consumer, the patient. A 39-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number; EN6208) via an unspecified route of administration in left arm on 15Mar2021 at 11:15 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Concomitant medications were not reported. The patient did not have any allergies to food, medication or other products. The patient does not have symptoms associated with COVID-19. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. The patient experienced soreness in muscles, not just at injection site but also in the back and thighs (muscle soreness and vaccination site pain) on 16Mar2021. The patient did not receive any treatment for the events. The clinical outcome of soreness in muscles and soreness at injection site were resolved on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
12/16/2020 I had a fever at night I woke up with fever and chills and body aches and I also had a pretty bad headache,  it lasted throughout the next day 12/17 I took tylenol and just felt tired, my headache was also off and on it just depended when I took tylenol
Second day was just a slight fever and fatigue, resolved on day 3rd day of symptoms.  However, on the 4th day, got numbness and tingling in  both legs up to above the knees. I also had numbness and tingling in hands and arms. These symptoms resolved in about 2.5 weeks.
Immediately post vax the pt developed a rash on her face - no respiratory distress. The rash faded within 30 minutes. Additional information received reported that the Tripedia was given in the right leg and the IPOL and Comvax were given in the left leg. No further information is expected. This case is closed.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site tenderness in a 65-year-old female patient who received SHINGRIX. On 1st May 2018, the patient received the 2nd dose of SHINGRIX. In May 2018, less than a week after receiving SHINGRIX, the patient experienced injection site tenderness and injection site erythema. On an unknown date, the outcome of the injection site tenderness and injection site erythema were unknown. It was unknown if the reporter considered the injection site tenderness and injection site erythema to be related to SHINGRIX. Additional information was received as follows: The patient experienced tenderness, redness, and softball size circle at injection site. The patient did not have further details. The vaccine was administered at another site (place).
Patient describes feeling nauseated, lightheaded, and dizzy about 20 minutes after vaccine while in waiting observation area. Mom states she looked over, patient's eyes were rolled back, she was shaking, and not responding to mom. Patient does not remember this part. She states the next thing she remembers is looking up at nurses looking down on her. Mom thinks she was out for a few minutes. Of note, patient had not had anything to eat or drink on day of vaccination. She also has a history of syncopal episode after a toradol injection, and with illness.
NO REDNESS OR SWELLING @ INJ. SITE  PT BECAME PALE, HEADACHE, NAUSEA, CHILLS, LOW GRADE TEMP.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 04Nov2022 at 12:00 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 56 years, in left arm for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: LAMICTAL, start date: 01Jan2018, stop date: 17Oct2023; DULOXETINE, start date: 01Jan2021, stop date: 17Oct2023. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19. Patient received Paxlovid for Treatment of COVID-19.  The information on the batch/lot number for bnt162b2, bnt162b2 omi ba.4-5 has been requested and will be submitted if and when received.
L deltoid area very red swollen and warm to the touch 3 days after injection per her mother's phone call report.
fever; chills; runny nose; chest tightness; This spontaneous case was reported by an other health care professional and describes the occurrence of PYREXIA (fever), CHILLS (chills), RHINORRHOEA (runny nose) and CHEST DISCOMFORT (chest tightness) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Asthma.   On 26-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever), CHILLS (chills), RHINORRHOEA (runny nose) and CHEST DISCOMFORT (chest tightness). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at a dose of UNK dosage form; ANTIHISTAMINES for Runny nose, at a dose of UNK dosage form and SALBUTAMOL SULFATE (ALBUTEROL [SALBUTAMOL SULFATE]) for Tight chest, at a dose of UNK dosage form. At the time of the report, PYREXIA (fever), CHILLS (chills), RHINORRHOEA (runny nose) and CHEST DISCOMFORT (chest tightness) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Body temperature: 41.667 (High) High.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Relevant concomitant medications were reported that is patient Is currently on blood pressure, cholesterol, anxiety and meds to help sleep.
At 16:00, pt complained of nausea, headache and "feeling sick" and pain on stomach and fever. At 19:00, she started vomiting and continues with pain. The next day at 09:00, she was home from school. She still has symptoms but not as severe.
VACCINE GIVEN IS UNKNOWN, WAS NOT WRITTEN ON PAPERWORK AND CAN NOT REACH PATIENT
Recurrent Acute pancreatitis; This literature-non-study case was reported in a literature article and describes the occurrence of PANCREATITIS ACUTE (Recurrent Acute pancreatitis) in a 12-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.       No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PANCREATITIS ACUTE (Recurrent Acute pancreatitis) (seriousness criterion medically significant). At the time of the report, PANCREATITIS ACUTE (Recurrent Acute pancreatitis) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered PANCREATITIS ACUTE (Recurrent Acute pancreatitis) to be related.    Concomitant and treatment medications were not reported.  Author present a case of an adolescent female without any known anatomic or metabolic pre-disposition, developing recurrent acute pancreatitis that was seemingly related to acute viral infection and COVID-19 vaccination. Company comment: This is a literature-non-study case concerning a 12-year-old female patient, with no medical history reported or any known anatomic or metabolic pre-disposition, who experienced the serious (due to medically significant) and unexpected AESI of pancreatitis acute, after receiving an unspecified booster dose of mRNA-1273 vaccine. The onset date of the event and the vaccination date were not reported; hence, latency cannot be assessed properly. No further clinical information was provided for medical reviewing. The author assessed an apparently relationship with acute viral infection and COVID-19 vaccination. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.